Kidney and pregnancy outcomes in pregnancy-associated atypical hemolytic uremic syndrome: A systematic review and meta-analysis
Open Access
- 31 January 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (5) , e41403
Abstract
Background: Pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) is a rare, life-threatening condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, elevated liver enzymes, and acute kidney injury. Prompt diagnosis and therapy are crucial due to the high risk of progression to chronic kidney disease (CKD), end-stage kidney disease (ESKD), and dialysis dependency, as well as significant maternal and fetal morbidity and mortality. Methods: A comprehensive literature search was conducted across EMBASE, MEDLINE, and the Cochrane CENTRAL from January 2000 to March 2024. Studies reporting on pregnancy and kidney outcomes in women diagnosed with p-aHUS were included. Results: Ten studies involving 386 pregnancies in 380 patients met the inclusion criteria for the final analysis. Renal outcomes varied, with mean creatinine levels ranging from 0.72 to 8.734 mg/dL. Dialysis was required in 66.6% of patients, and 25% developed ESKD. Maternal complications included preeclampsia (36.4%) and hemolysis, elevated liver enzymes, and low platelets syndrome (29.7%), with a 5% maternal mortality rate. Fetal complications included intrauterine fetal demise (n = 25), intrauterine growth restriction, low birth weight, and prematurity. Treatment with eculizumab significantly reduced the risk of CKD and ESKD, with a pooled risk ratio of 0.20 (95% confidence interval: 0.09–0.44) and low heterogeneity (I² = 0%, P = .43). Conclusion: This analysis highlights the severe kidney and pregnancy outcomes associated with p-aHUS. Eculizumab treatment is significantly beneficial in reducing the risk of CKD and ESKD.Keywords
This publication has 20 references indexed in Scilit:
- Eculizumab for pregnancy-related atypical hemolytic uremic syndromeNephrology Dialysis Transplantation, 2024
- Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysisJournal Of Nephrology, 2021
- Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome RegistryKidney International Reports, 2019
- Postpartum Renal Cortical Necrosis Is Associated With Atypical Hemolytic Uremic Syndrome in Developing CountriesKidney International Reports, 2019
- A retrospective study of pregnancy-associated atypical hemolytic uremic syndromeKidney International, 2018
- Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceKidney International, 2017
- Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumabNephrology Dialysis Transplantation, 2016
- Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label TrialAmerican Journal of Kidney Diseases, 2016
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Hemolytic-uremic syndrome in Switzerland: a nationwide surveillance 1997–2003European Journal of Pediatrics, 2009